Royal Bank Of Canada Bolt Biotherapeutics, Inc. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.73 - $1.5 $260 - $535	357 Added 35700.0%	358 $0
Q1 2024 Nov 05, 2024	SELL	$1.01 - $1.4 $360 - $499	-357 Reduced 99.72%	1 $0
Q1 2024 May 15, 2024	SELL	$1.01 - $1.4 $468 - $649	-464 Reduced 99.78%	1 $0
Q4 2023 Feb 14, 2024	BUY	$0.85 - $1.12 $315 - $415	371 Added 394.68%	465 $0
Q3 2023 Nov 14, 2023	BUY	$0.98 - $1.46 $92 - $137	94 New	94 $0
Q2 2022 Aug 15, 2022	SELL	$1.41 - $2.91 $572 - $1,181	-406 Reduced 28.88%	1,000 $2,000
Q1 2022 May 16, 2022	SELL	$2.74 - $4.82 $8,691 - $15,289	-3,172 Reduced 69.29%	1,406 $4,000
Q4 2021 Feb 14, 2022	BUY	$4.19 - $13.97 $8,970 - $29,909	2,141 Added 87.85%	4,578 $22,000
Q3 2021 Nov 15, 2021	BUY	$11.15 - $18.6 $18,319 - $30,559	1,643 Added 206.93%	2,437 $31,000
Q2 2021 Aug 16, 2021	BUY	$15.4 - $31.46 $12,227 - $24,979	794 New	794 $12,000

19.1M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $18.8M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.